What is Hyperion Biotechnology?
Founded in 1998 and headquartered in San Antonio, Texas, Hyperion Biotechnology operates as a specialized biomedical and clinical research entity. As an 8(m) woman-owned and service-disabled veteran-owned small business, the company leverages its status as a certified HUB vendor to provide critical program support to the U.S. Department of Defense and various government agencies. Their service portfolio is expansive, encompassing logistics, medical advisory, and streamlined program management designed to enhance operational efficiencies. By integrating scientific rigor with administrative expertise, Hyperion Biotechnology has established itself as a reliable partner for mission-critical projects that demand both technical precision and regulatory compliance.
How much funding has Hyperion Biotechnology raised?
Hyperion Biotechnology has raised a total of $680K across 2 funding rounds:
Debt
$350K
Debt
$330K
Debt (2020): $350K with participation from PPP
Debt (2021): $330K led by PPP
Key Investors in Hyperion Biotechnology
PPP
Public-Private Partnership
What's next for Hyperion Biotechnology?
With the recent influx of capital, Hyperion Biotechnology is well-positioned to scale its service offerings and deepen its penetration within the federal contracting landscape. The company's strategic roadmap likely involves expanding its clinical research capabilities and enhancing its logistics infrastructure to meet the evolving needs of its government clientele. By focusing on process optimization and the integration of advanced technology-driven services, Hyperion aims to maintain its competitive edge as a trusted advisor and service provider. Future growth will likely be characterized by a continued emphasis on securing long-term government contracts and diversifying its advisory services to address the increasing complexity of modern biomedical and defense programs.
See full Hyperion Biotechnology company page
